CTRI/2019/06/019686
Completed
Phase 2
Clinical study on the immune enhancing effect of Amalakyadi Rasayan in children
ational Institute of Ayurveda Jaipur0 sites60 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Health Condition 1: J30-J39- Other diseases of upper respiratory tract
- Sponsor
- ational Institute of Ayurveda Jaipur
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Children aged from 1\-10 years of either sex.
- •2\.Children with recurrent respiratory infections.
Exclusion Criteria
- •1\.Subjects suffering from major systemic illness necessitating long term treatment
- •2\.Subjects with evidence of malignancy
- •3\.Subjects with concurrent serious hepatic dysfunction (defined as AST and/or ALT \>3 times of the upper normal limit) or renal dysfunction (defined as S.creatinine \>1\.2mg/dl), uncontrolled pulmonary dysfunction (asthmatic and COPD patients)
- •4\.Co\-morbidity like TB, UTI and bleeding disorders etc
- •5\.H/o hypersensitivity to any of the trial drug or their ingredients
- •6\.Subjects who have completed participation in any other clinical trial during the past six months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Clinical Study on the immune Enhancing Effect of Nidigdhikadi Leha on Upper Respiratory Tract Infections (URTI)Health Condition 1: J399- Disease of upper respiratory tract, unspecifiedCTRI/2020/08/027386ational Institute of Ayurveda Jaipur
Completed
Phase 2
To study the effect of Swarnaprashan in reducing the frequency of illness in children by improving the immunity and increasing the body strength.CTRI/2021/05/033713ational Institute of Ayurveda Jaipur Rajasthan30
Suspended
Phase 1
Evaluation of immunological parameters in high risk group of cancer treated with immune-cell therapyJPRN-jRCTc030200090Takimoto Rishu20
Suspended
Phase 1
Evaluation of immunological parameters in high risk group of cancer treated with immune-cell therapynoneJPRN-jRCTc030200091Takimoto Rishu20
Suspended
Phase 1
Evaluation of immunological parameters in high risk group of cancer treated with immune-cell therapyJPRN-jRCTc030200089Takimoto Rishu20